NCT04648319View on ClinicalTrials.gov

A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

January 17, 2022

Study Completion Date

January 17, 2022

Conditions
Cholangiocarcinoma
Interventions
DRUG

BMS-936558

BMS-936558 followed by 30 grays of 3 to 5 fractions of high dose SBRT followed by monthly BMS-936558 until progression

Trial Locations (4)

1000

Institut Jule Bordet, Brussels

1200

Cliniques universitaires Saint-Luc, Brussels

Unknown

American University of Beirut Medical Center, Beirut

Centre hospitalier de Luxembourg, Luxembourg

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

American University of Beirut Medical Center

OTHER

NCT04648319 - A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | Biotech Hunter | Biotech Hunter